Dr Rhian Thomas

Dr Rhian Thomas

Senior Lecturer, Pharmacy
+44 (0) 1792 987125
JavaScript is required to view this email address.
Available For Postgraduate Supervision
Institute of Life Science 1 internal Atrium view up.jpg
Dr Rhian Thomas

Dr Rhian Thomas

Senior Lecturer, Pharmacy

Telephone number

+44 (0) 1792 987125
Available For Postgraduate Supervision


Dr Rhian Thomas is a Senior Lecturer in Pharmacy within Swansea University Medical School.  She is an experienced academic having worked in education and research in a number of UK HE institutions and is a Fellow of the HEA. She was previously a Senior Lecturer in Human Physiology at UWE, Bristol where she taught on the Biomedical Sciences and Healthcare Sciences programmes.  While at UWE she was the Programme Lead for the BSc (Hons) Healthcare Science (Physiological Sciences) degree apprenticeship, part of UWE Bristol’s unique collaboration with NHS providers that allowed students to ‘earn and learn’ through in-post NHS training.  Prior to this she was a lecturer in Pharmacology and Physiology in the School of Pharmacy and Pharmaceutical Sciences at Cardiff University. Her research interests, both as a postdoctoral researcher and as an academic, are in the biology of disease especially neurodegeneration.  Much of her teaching covers the functioning and disorders of the nervous system.  

Areas Of Expertise

  • Alzheimer’s disease
  • Neurodegeneration
  • Molecular Neuroscience
  • Antibody based therapies
  • Scientific data analysis
  • Cell biology of disease
  • Physiology and Pharmacology
  • Health Sciences Education

Career Highlights

Teaching Interests

Dr Rhian Thomas’ key teaching interests are in physiology, pharmacology, scientific skills, data analysis.

Key taught modules include:

PMP101: Health, Disease and Patient (HDP)



Dr Thomas’ research has been directed at the biology of a variety of diseases covering  the respiratory, skeletal and nervous system.  She is particularly interested in neurodegeneration, in particular amyloid production in Alzheimer's disease (AD). 

There are two characteristic neuropathological features of AD, neurofibrillary tangles made of hyperphosphorylated tau and extracellular senile plaques made primarily of amyloid-beta, a 40-43 amino acid peptide produced from amyloid precursor protein (APP). An increase in amyloid-beta levels (especially amyloid-beta 42) is thought to be crucial for the pathogenesis of AD. Her primary focus has been on investigating how amyloid-beta is produced in Alzheimer's disease, what affects this, how this contributes to neurodegeneration and developing therapies to influence this. 

Award Highlights

PATENT  Kidd, E.J., Thomas, R.S. and Liddell, J.E. 2008. British patent application No. 0720912.5, Antibody for Alzheimer’s disease – Case UC3.28, ‘Monoclonal antibody for APP’, filed 23/10/08. Filed in Europe and USA.